The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,100 and keeps an Overweight rating on the shares. The firm ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

Adds Regeneron comment Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed ...

in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court. "We have considered Regeneron's remaining arguments and find them unpersuasive," the appeals court wrote ...

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...

Eylea’s sales in the United States declined 11% year over year to $1.2 billion, primarily due to increased competition. Please note that Regeneron co-developed Eylea with the HealthCare unit of ...

Eylea biosimilar, which UBS analyst Trung Huynh tells investors in “negative, but somewhat expected” for Regeneron (REGN). While extended timelines for an additional appeal is likely ...

As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%. This legal setback for Regeneron comes amid competitive pressures in the ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...